These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24911662)

  • 1. Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing.
    Cuffe S; Hon H; Qiu X; Tobros K; Wong CK; De Souza B; McFarlane G; Masroor S; Azad AK; Hasani E; Rozanec N; Leighl N; Alibhai S; Xu W; Issa AM; Liu G
    Pharmacogenet Genomics; 2014 Jul; 24(7):348-55. PubMed ID: 24911662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing patient readiness for the clinical adoption of personalized medicine.
    Issa AM; Tufail W; Hutchinson J; Tenorio J; Baliga MP
    Public Health Genomics; 2009; 12(3):163-9. PubMed ID: 19204419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Women's interest in gene expression analysis for breast cancer recurrence risk.
    O'Neill SC; Brewer NT; Lillie SE; Morrill EF; Dees EC; Carey LA; Rimer BK
    J Clin Oncol; 2007 Oct; 25(29):4628-34. PubMed ID: 17925559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic testing for the risk of developing late effects among survivors of childhood cancer: Consumer understanding, acceptance, and willingness to pay.
    Georgiou G; Wakefield CE; McGill BC; Fardell JE; Signorelli C; Hanlon L; Tucker K; Patenaude AF; Cohn RJ
    Cancer; 2016 Sep; 122(18):2876-85. PubMed ID: 27258553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of routine pharmacogenomic screening-Are we there yet? A perspective on the costs and benefits of routine screening-shouldn't everyone have this done?
    Veenstra DL
    Clin Pharmacol Ther; 2016 Feb; 99(2):164-6. PubMed ID: 26565561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attitudes toward colon cancer gene testing: survey of relatives of colon cancer patients.
    Petersen GM; Larkin E; Codori AM; Wang CY; Booker SV; Bacon J; Giardiello FM; Boyd PA
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 2):337-44. PubMed ID: 10207638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Willingness of Students of Economics to Pay for Predictive Oncological Genetic Testing - An Empirical Analysis].
    Siol V; Lange A; Prenzler A; Neubauer S; Frank M
    Gesundheitswesen; 2017 May; 79(5):425-437. PubMed ID: 28575925
    [No Abstract]   [Full Text] [Related]  

  • 8. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey.
    Stanek EJ; Sanders CL; Taber KA; Khalid M; Patel A; Verbrugge RR; Agatep BC; Aubert RE; Epstein RS; Frueh FW
    Clin Pharmacol Ther; 2012 Mar; 91(3):450-8. PubMed ID: 22278335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy in elderly women with breast cancer: patients' perspectives on information giving and decision making.
    Harder H; Ballinger R; Langridge C; Ring A; Fallowfield LJ
    Psychooncology; 2013 Dec; 22(12):2729-35. PubMed ID: 23813806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: prescription for progress?
    Topol EJ
    Sci Transl Med; 2010 Aug; 2(44):44cm22. PubMed ID: 20702854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Willingness to pay for genetic testing: a study of attitudes in a Canadian population.
    Ries NM; Hyde-Lay R; Caulfield T
    Public Health Genomics; 2010; 13(5):292-300. PubMed ID: 19864872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacogenomics: hype or hope?].
    Schwab M; Schaeffeler E; Zanger UM; Brauch H; Kroemer HK
    Dtsch Med Wochenschr; 2011 Mar; 136(10):461-7. PubMed ID: 21365522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer.
    Miller PJ; Balu S; Buchner D; Walker MS; Stepanski EJ; Schwartzberg LS
    J Med Econ; 2013 Oct; 16(10):1179-89. PubMed ID: 23919632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing.
    Matro JM; Ruth KJ; Wong YN; McCully KC; Rybak CM; Meropol NJ; Hall MJ
    J Genet Couns; 2014 Dec; 23(6):1002-11. PubMed ID: 24794065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decisions on pharmacogenomic tests in the USA and Germany.
    Wegwarth O; Day RW; Gigerenzer G
    J Eval Clin Pract; 2011 Apr; 17(2):228-35. PubMed ID: 20846315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knowledge and attitudes of oncology nurses regarding pharmacogenomic testing.
    Dodson C
    Clin J Oncol Nurs; 2014 Aug; 18(4):E64-70. PubMed ID: 25095306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic testing in cancer: patient knowledge, attitudes, and expectations.
    Blanchette PS; Spreafico A; Miller FA; Chan K; Bytautas J; Kang S; Bedard PL; Eisen A; Potanina L; Holland J; Kamel-Reid S; McPherson JD; Razak AR; Siu LL
    Cancer; 2014 Oct; 120(19):3066-73. PubMed ID: 24962202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of pharmacists' expectations towards pharmacogenomics.
    de Denus S; Letarte N; Hurlimann T; Lambert JP; Lavoie A; Robb L; Sheehan NL; Turgeon J; Vadnais B
    Pharmacogenomics; 2013 Jan; 14(2):165-75. PubMed ID: 23327577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric pharmacists' perception on the use of pharmacogenomic testing in the mental health population.
    Shishko I; Almeida K; Silvia RJ; Tataronis GR
    Pharmacogenomics; 2015; 16(9):949-58. PubMed ID: 26100610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.